甲状腺激素类似物:研究进展
甲状腺激素类似物旨在利用甲状腺激素对脂代谢的作用而避免心脏毒性,基于TRα和TRβ分别介导心脏与代谢效应的分布差异,开发了GC-1、KB-2115、MB07344/VK2809和MGL-3196等TRβ选择性类似物。这些化合物均能降低低密度脂蛋白胆固醇,但eprotirome的3期试验因肝酶显著升高及动物软骨副作用报告而中止,其他项目也随之终止。近年TRβ激动剂在非酒精性脂肪性肝病治疗中重新受到关注,MGL-3196和VK2809的临床试验初步报告令人鼓舞;此外3,5,3'-三碘甲腺乙酸已用于TRβ突变所致甲状腺激素抵抗,并在Allan-Herndon-Dudley综合征中报告了有趣结果,而T2和T1AM尚处于不同研究阶段。
要点
- TRβ选择性类似物可降低低密度脂蛋白胆固醇,但eprotirome的3期试验因肝酶显著升高及动物软骨副作用而中止。
- MGL-3196和VK2809在非酒精性脂肪性肝病临床试验中的初步报告令人鼓舞。
- 3,5,3'-三碘甲腺乙酸已用于部分TRβ突变所致甲状腺激素抵抗的治疗。
核心结论
- TRβ选择性甲状腺激素类似物在降低低密度脂蛋白胆固醇方面有效,但eprotirome的3期试验因肝酶显著升高及动物软骨副作用报告而中止,其他项目也随之终止;近年TRβ激动剂在非酒精性脂肪性肝病治疗中重新受到关注,MGL-3196和VK2809的初步临床试验报告令人鼓舞。
研究设计与样本
- 综述,未报告系统检索范围。
主要发现
- GC-1(sobetirome)、KB-2115(eprotirome)、MB07344/VK2809和MGL-3196(resmetirom)四种化合物已在临床试验中使用,每种均能降低低密度脂蛋白胆固醇。
- eprotirome的3期试验因肝酶显著升高及同期报告的动物软骨副作用而中止,其他项目也随之终止。
- MGL-3196和VK2809在实验模型取得优秀结果后已启动非酒精性脂肪性肝病临床试验,初步报告令人鼓舞。
- sobetirome在脱髓鞘疾病实验模型中也显示有效。
- 3,5,3'-三碘甲腺乙酸已用于部分TRβ突变所致甲状腺激素抵抗的治疗,并在Allan-Herndon-Dudley综合征患者中报告了有趣结果。
临床怎么用
- 3,5,3'-三碘甲腺乙酸已用于部分TRβ突变所致甲状腺激素抵抗的治疗。
- 3,5-二碘甲状腺原氨酸(T2)在大鼠血脂异常和非酒精性脂肪性肝病模型中成功使用,但合成T2类似物的临床试验结果令人失望。
- 3-碘甲状腺胺(T1AM)在β-淀粉样蛋白或惊厥剂诱导的神经损伤动物模型中取得有希望的结果,但迄今尚无临床数据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The development of thyroid hormone (TH) analogues was prompted by the attempt to exploit the effects of TH on lipid metabolism, avoiding cardiac thyrotoxicosis. Analysis of the relative distribution of the α and β subtypes of nuclear TH receptors (TRα and TRβ) showed that TRα and TRβ are responsible for cardiac and metabolic responses, respectively. Therefore, analogues with TRβ selectivity were developed, and four different compounds have been used in clinical trials: GC-1 (sobetirome), KB-2115 (eprotirome), MB07344/VK2809, and MGL-3196 (resmetirom). Each of these compounds was able to reduce low-density lipoprotein cholesterol, but a phase 3 trial with eprotirome was interrupted because of a significant increase in liver enzymes and the contemporary report of cartilage side effects in animals. As a consequence, the other projects were terminated as well. However, in recent years, TRβ agonists have raised new interest for the treatment of nonalcoholic fatty liver disease (NAFLD). After obtaining excellent results in experimental models, clinical trials have been started with MGL-3196 and VK2809, and the initial reports are encouraging. Sobetirome turned out to be effective also in experimental models of demyelinating disease. Aside TRβ agonists, TH analogues include some TH metabolites that are biologically active on their own, and their synthetic analogues. 3,5,3'-triiodothyroacetic acid has already found clinical use in the treatment of some cases of TH resistance due to TRβ mutations, and interesting results have recently been reported in patients with the Allan-Herndon-Dudley syndrome, a rare disease caused by mutations in the TH transporter MCT8. 3,5-diiodothyronine (T2) has been used with success in rat models of dyslipidemia and NAFLD, but the outcome of a clinical trial with a synthetic T2 analogue was disappointing. 3-iodothyronamine (T1AM) is the last entry in the group of active TH metabolites. Promising results have been obtained in animal models of neurological injury induced by β-amyloid or by convulsive agents, but no clinical data are available so far.
引用
- Zucchi R. Thyroid Hormone Analogues: An Update. Thyroid. 2020. PMID: 32098589. doi:10.1089/thy.2020.0071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。